FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and aims at diagnosis of individual fibroid disease. Method for diagnosing a fibroid disease based on an increased level of soluble VAP-1 or SSAO level in body fluids and using a complement in a diagnostic method are disclosed.
EFFECT: group of inventions allows to expand the arsenal of diagnostic tools.
9 cl, 19 dwg, 8 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF VAP-1 INHIBITORS FOR FIBROTIC SICKNESS TREATMENT | 2010 |
|
RU2580626C2 |
| METHOD OF TREATING NEPHROPATHY | 2014 |
|
RU2718054C2 |
| NEW COMPLETELY HUMAN VAP-1 MONOCLONAL ANTIBODIES | 2008 |
|
RU2459832C2 |
| AGENT FOR TREATING RENAL FIBROSIS | 2011 |
|
RU2711531C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| MEANS FOR KIDNEY FIBROSIS TREATMENT | 2011 |
|
RU2635460C2 |
| INTEGRIN ανβ8 NEUTRALISING ANTIBODIES | 2011 |
|
RU2565539C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY FIBROUS DISEASES | 2010 |
|
RU2561672C2 |
| ANTIBODIES TO CONNECTIVE TISSUE GROWTH FACTOR | 2004 |
|
RU2330861C2 |
| HUMANISED ANTI-TGF-BETA-ANTIBODY | 2005 |
|
RU2386638C2 |
